Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56358 | 0.89 | MAPT (0.50) | MAPTPKMALDH1A1TSHRTDP1 | |
| SCHEMBL166184 | 0.86 | MAPT (0.48) | MAPTPKMALDH1A1TDP1MAPK1 | |
| SCHEMBL6698344 | 0.86 | MAPT (0.48) | MAPTPKMALDH1A1TSHRTDP1 | |
| SCHEMBL30774320 | 0.82 | MAPT (0.64) | MAPTPKMALDH1A1TSHRTDP1 | |
| SCHEMBL2070426 | 0.82 | MAPT (0.46) | MAPTPKMALDH1A1TDP1MAPK1 | |
| SCHEMBL8170040 | 0.80 | PKM (0.42) | MAPTPKMALDH1A1TSHRTDP1 | |
| SCHEMBL29427889 | 0.80 | MAPT (0.43) | MAPTPKMALDH1A1TDP1MAPK1 | |
| SCHEMBL28929673 | 0.80 | MAPT (0.43) | MAPTPKMALDH1A1TDP1MAPK1 | |
| SCHEMBL25239556 | 0.78 | MAPT (0.43) | MAPTPKMALDH1A1TDP1MAPK1 | |
| SCHEMBL12064766 | 0.78 | DPP4 (0.43) | MAPTALDH1A1TDP1MAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038917-A1 | HETEROARYL AMINE COMPOUNDS AND USES THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2025-02-20 | — | — | WO | disclosed |
| WO-2025038930-A1 | AZEPANE AND PYRROLIDINE COMPOUNDS AND USES THEREOF | XENON PHARMACEUTICALS, INC. (CA) | 2025-02-20 | — | — | WO | disclosed |
| WO-2025038920-A1 | HETEROARYL AMINE COMPOUNDS AND USES THEREOF | XENON PHARMACEUTICALS, INC. (CA) | 2025-02-20 | — | — | WO | disclosed |
| EP-3191449-B1 | COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-07-01 | — | — | EP | disclosed |
| EP-3191449-B1 | COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-07-01 | — | — | EP | disclosed |
| CN-107250110-B | Novel compounds as inhibitors of transfection Rearrangement (RET) | 葛兰素史克知识产权发展有限公司 | 2020-04-24 | — | — | CN | disclosed |
| US-10294236-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-05-21 | — | — | US | disclosed |
| US-10294236-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-05-21 | — | — | US | disclosed |
| US-20180099976-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
| US-20180099976-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
| US-20130005743-A1 | New positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2013-01-03 | — | — | US | disclosed |
| US-20130005743-A1 | New positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2013-01-03 | — | — | US | disclosed |
| US-20130005743-A1 | New positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2013-01-03 | — | — | US | disclosed |
| US-20120258978-A1 | NITROGEN-CONTAINING SIX-MEMBERED AROMATIC RING DERIVATIVES AND PHARMACEUTICAL PRODUCTS CONTAINING THE SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-10-11 | — | — | US | disclosed |
| US-20120258978-A1 | NITROGEN-CONTAINING SIX-MEMBERED AROMATIC RING DERIVATIVES AND PHARMACEUTICAL PRODUCTS CONTAINING THE SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-10-11 | — | — | US | disclosed |
| US-20120258978-A1 | NITROGEN-CONTAINING SIX-MEMBERED AROMATIC RING DERIVATIVES AND PHARMACEUTICAL PRODUCTS CONTAINING THE SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-10-11 | — | — | US | disclosed |
| US-20100130739-A1 | NITROGEN-CONTAINING SIX-MEMBERED AROMATIC RING DERIVATIVES AND PHARMACEUTICAL PRODUCTS CONTAINING THE SAME | ASUBIO PHARMA CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130739-A1 | NITROGEN-CONTAINING SIX-MEMBERED AROMATIC RING DERIVATIVES AND PHARMACEUTICAL PRODUCTS CONTAINING THE SAME | ASUBIO PHARMA CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130739-A1 | NITROGEN-CONTAINING SIX-MEMBERED AROMATIC RING DERIVATIVES AND PHARMACEUTICAL PRODUCTS CONTAINING THE SAME | ASUBIO PHARMA CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2151439-A1 | NITROGENATED AROMATIC 6-MEMBERED RING DERIVATIVE, AND PHARMACEUTICAL AGENT COMPRISING THE SAME | Asubio Pharma Co., Ltd. (JP) | 2010-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258978-A1 | NITROGEN-CONTAINING SIX-MEMBERED AROMATIC RING DERIVATIVES AND PHARMACEUTICAL PRODUCTS CONTAINING THE SAME | NGF, VEGFA, BDNF | MAPT 1674/4885PKM 3868/4885ALDH1A1 3305/4885 |
| US-10294236-B2 | Compounds as rearranged during transfection (RET) inhibitors | RET, FER, THRB | MAPT 1615/4885PKM 1996/4885ALDH1A1 2176/4885 |
| US-20130005743-A1 | New positive allosteric modulators of nicotinic acetylcholine receptor | CHRNG, CHRNA7, CHRNA1 | MAPT 755/4885PKM 2694/4885ALDH1A1 4066/4885 |
| US-20100130739-A1 | NITROGEN-CONTAINING SIX-MEMBERED AROMATIC RING DERIVATIVES AND PHARMACEUTICAL PRODUCTS CONTAINING THE SAME | NGF, VEGFA, NRP1 | MAPT 1633/4885PKM 4116/4885ALDH1A1 2632/4885 |
| US-20180099976-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | RET, FER, THRB | MAPT 1673/4885PKM 2116/4885ALDH1A1 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.